Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
- 11 February 2016
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 127 (6), 703-712
- https://doi.org/10.1182/blood-2015-08-660977
Abstract
Key Points Ponatinib induces durable responses regardless of baseline BCR-ABL1 mutation status in CP-CML patients. No single or compound mutant consistently confers primary or secondary resistance to ponatinib in CP-CML.Keywords
This publication has 26 references indexed in Scilit:
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaCancer Cell, 2014
- Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBlood, 2014
- Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombinationBlood, 2014
- Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibLeukemia, 2014
- Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencingEuropean Journal of Cancer, 2014
- Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVJournal of Clinical Oncology, 2014
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasThe New England Journal of Medicine, 2013
- Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainBlood, 2013
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistanceBritish Journal of Cancer, 2013